Bimzelx®▼ Europe In the European Union, Bimzelx® (bimekizumab) is indicated forPlaque psoriasisBimzelx® is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy Psoriatic arthritisBimzelx®, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs).Axial spondyloarthritisNon-radiographic axial spondyloarthritis (nr-axSpA)Bimzelx® is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) who have responded inadequately or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).Ankylosing spondylitis (AS, radiographic axial spondyloarthritis)Bimzelx® is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy. Hidradenitis suppurativa (HS)Bimzelx® is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic HS therapy. USA In the US, Bimzelx® (bimekizumab) is indicated for Plaque PsoriasisBimzelx® is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.Psoriatic ArthritisBimzelx® is indicated for the treatment of adults with active psoriatic arthritis.Non-Radiographic Axial SpondyloarthritisBimzelx® is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation.Ankylosing SpondylitisBimzelx® is indicated for the treatment of adults with active ankylosing spondylitis.Hidradenitis SuppurativaBimzelx® is indicated for the treatment of adults with moderate to severe hidradenitis suppurativa. Prescribing information European Union Bimzelx® SmPC (Sourced from www.ema.europa.eu) ▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Prescribing information USA Bimzelx® (bimekizumab) injection, for subcutaneous use
